摘要
背景与目的:近年研究表明,抑癌基因p16表达缺失及失活在人类多种肿瘤发生发展过程中发挥重要作用,但其与垂体腺瘤之间的关系研究甚少,本研究旨在探讨垂体腺瘤中p16基因表达情况及其与肿瘤临床病理特点、侵袭性、复发之间的关系。方法:用RT-PCR、Westernblot方法分别检测70例垂体腺瘤及10例正常脑组织中p16mRNA、p16蛋白表达情况,并结合临床病理进行探讨。结果:74.3%(52/70)垂体腺瘤中的p16mRNA、p16蛋白表达缺失或低下,侵袭性腺瘤、复发腺瘤p16表达缺失率均分别高于非侵袭腺瘤及非复发腺瘤,但统计学处理各组间无显著差异(P>0.05);p16表达缺失肿瘤的平均直径为(22.1±7.2)mm,明显大于阳性表达肿瘤的直径(8.1±4.5)mm(P<0.01)。此外,p16基因表达与垂体腺瘤其它临床病理特点均无显著相关。结论:在垂体腺瘤中存在较普遍的p16基因转录抑制及表达低下,其失活可能在垂体腺瘤形成早期发挥重要作用,并对肿瘤生长及生物学行为演变起一定促进作用。
BACKGROUND & OBJECTIVE:The inactivation and low expression of tumor suppressor gene p16 has been found to play an important role in the tumorigenesis of a wide variety of human tumors, but its association with human pituitary adenomas was not clear. This study was conducted to investigate the relationship between p16 gene expression and clinicopathologic features including invasiveness and recurrence in pituitary adenoma patients.METHODS:The p16 mRNA and p16 protein expression levels were examined using reverse transcription polymerase chain reaction (RT PCR) and Western Blot analysis respectively in 70 pituitary adenomas and 10 normal brain tissues. RESULTS:Fifty two of 70(74.3%) tumor samples presented loss or low p16 mRNA and p16 protein. The invasive and recurrent adenomas had higher loss expression rates than noninvasive and nonrecurrent group respectively; however,there was no significant difference (P >0.05). Moreover, the mean diameter of adenomas without p16 expression was obviously larger than that of p16 positive tumors (22 1±7 2 mm versus 8 1±4 5 mm,P< 0 01). There was no association between p16 expression and other clinicopathologic features of pituitary adenomas. CONCLUSION:These findings suggested that p16 down regulation may play an important role in the initial tumorigenesis,growth,and biological behavior of pituitary adenomas.
出处
《癌症》
SCIE
CAS
CSCD
北大核心
2003年第2期198-201,共4页
Chinese Journal of Cancer
